Cost-utility of aspirin and proton pump inhibitors for primary prevention
about
Aspirin for primary prevention of cardiovascular diseaseEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsAspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.Risk score to predict gastrointestinal bleeding after acute ischemic strokeEstimates of benefits and harms of prophylactic use of aspirin in the general population.Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost.Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerationsThe decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menHealth Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.Acid-NSAID/aspirin interaction in peptic ulcer disease.A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention.Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.What you need to know when you prescribe a proton pump inhibitor.Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial.
P2860
Q26774150-F692D7AD-D805-43BA-9215-A3F64AA7293FQ26995752-65876204-851E-432D-B4C0-6B0B016C2854Q30457290-76F96D86-04A7-415F-B580-BBFCB266EC28Q33611577-8D7B8DBB-F535-4FBE-9C7B-8910CADB3B30Q33936082-5E9C9A48-4254-4284-999B-C7DA2BF1D418Q33997632-591E0904-7089-4324-A49C-805ECEA884EFQ34432503-78B17F54-7CC6-4F60-949F-692C54E4F9EAQ35196095-40761871-D65E-4FE6-B89D-88F4EA91745BQ36754513-964B3CBD-D889-4067-BD21-0D34D28EAE41Q37098181-8CF0D226-3213-4F7F-86B2-5F7EEB87AB3CQ37231429-8D2618B9-64E9-486D-A487-A5A1BB6BE8ABQ37567490-A18AB670-F3E1-4CF7-9E1F-BA040BA03EF5Q37957700-F5F8EA99-DD4D-4567-844D-D9E24499B475Q38044398-AF8FFADF-6BF5-4BF0-93FA-BA0857AAB1AAQ38183305-A0C9264C-EFC3-4791-94AE-2AF417C07EF5Q39746156-F6797CB2-38AB-4099-8D26-091EF7243210Q41060355-7D8D6BE4-1C95-4175-8098-9F066E7F40F6Q44472215-12D0BAD0-09B2-4589-82B6-2D508BEB06ED
P2860
Cost-utility of aspirin and proton pump inhibitors for primary prevention
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@ast
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@en
type
label
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@ast
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@en
prefLabel
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@ast
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@en
P2093
P2860
P1476
Cost-utility of aspirin and proton pump inhibitors for primary prevention
@en
P2093
A Mark Fendrick
Cheryl McDade
James Scheiman
Stephanie R Earnshaw
P2860
P304
P356
10.1001/ARCHINTERNMED.2010.525
P407
P577
2011-02-01T00:00:00Z